Reducing time for clinical NGS test interpretation by 85%

Ravindra Kolhe MD, PhD, Director of the Georgia Esoteric Molecular Laboratory at Augusta University

and

Peter Wild, PhD, Director of Senckenberg Institute for Pathology, University Hospital, Frankfurt, Germany

Next-Generation Sequencing (NGS) is becoming widely used for biomarker detection in myeloid leukemia and lung cancer samples, allowing testing of multiple markers at the same time. We will explore how 2x pre-optimized assays on the QIAGEN NGS system have allowed laboratories to detect and call challenging variants in myeloid and lung cancer. The QIAGEN NGS System*, using the QIAact Myeloid DNA UMI panel and a custom lung cancer assay, offers a complete Sample to Insight solution including bioinformatics tailored and optimized for the panel’s analysis and reporting, using QCI Analyze and QCI Interpret.

*The GeneReader NGS System is for research use only. Not for use in diagnostic procedures.

Follow us on: